Skip to main content
SpringerLink
Log in

Antineoplastics

Lack of efficacy during treatment of ovarian cancer, and hand-foot syndrome and gastrointestinal reactions following off label use: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The frequency of rivoceranib administration was mentioned as qod in case presentation; however, it is mentioned as daily in discussion. Therefore, the frequency of rivoceranib administration was considered qod (every other day) as per case presentation.

Reference

  • Xiao C, et al. Endostar plus apatinib successfully achieved long term progression-free survival in refractory ovarian cancer: A case report and literature review. OncoTargets and Therapy 14: 5363-5372, 2021. Available from: URL: http://doi.org/10.2147/OTT.S335139

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1893, 45 (2022). https://doi.org/10.1007/s40278-022-09828-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-09828-y

Search

Navigation